Massachusetts Medicaid spending on GLP-1 drugs

How much did Massachusetts Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $404.5 million for GLP-1 drugs paid through Massachusetts Medicaid in 2025, across at least 399,030 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 98 rows of 345, so these figures are floors.

Pharmacies were reimbursed at least $121.2 million for GLP-1 drugs paid through Massachusetts Medicaid in 2026 (quarter 1 only, as posted so far), across at least 116,367 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 23 rows of 83, so these figures are floors.

By year and ingredient

2020at least $10,280,804No dataat least $8,632,379at least $34,833,969at least $1,562,179at least $223,633$255,370at least $55,788,334
2021at least $5,823,787No dataat least $9,367,602at least $71,323,813at least $735,305at least $146,235at least $185,689at least $87,582,432
2022at least $9,730,958at least $261,098at least $8,598,468at least $105,411,127at least $386,410at least $102,691at least $130,279at least $124,621,031
2023at least $22,275,102at least $9,676,891at least $9,803,846at least $142,284,421at least $250,023at least $26,661at least $58,328at least $184,375,272
2024at least $130,064,851at least $38,128,406at least $4,399,349at least $100,188,354at least $225,078Suppressedat least $7,621at least $273,013,658
2025at least $53,880,399at least $278,792,511at least $737,841at least $71,069,396at least $19,402Suppressedat least $20,273at least $404,519,821
2026 (Q1)at least $9,593,310at least $98,003,513at least $114,665at least $13,460,384SuppressedSuppressedSuppressedat least $121,171,872

By product, 2025

Ozempicat least $39,576,377at least 41,4612 of 26
Rybelsus$2,600,2172,7190 of 24
Wegovyat least $11,703,805at least 9,1672 of 42
Mounjaroat least $63,110,306at least 61,27411 of 59
Zepboundat least $215,682,205at least 208,11514 of 62
Liraglutide (generic name listing)at least $63,554at least 12129 of 36
Saxendaat least $135,174at least 1152 of 8
Victoza$539,1138890 of 16
Trulicityat least $71,069,396at least 75,1287 of 39
Bydureonat least $19,402at least 253 of 4
ByettaSuppressedSuppressed7 of 7
Exenatide (generic name listing)SuppressedSuppressed7 of 7
SoliquaSuppressedSuppressed8 of 8
Xultophyat least $20,273at least 166 of 7

By quarter, 2025

Q1 2025at least $87,871,293at least 87,72027 of 90
Q2 2025at least $98,755,197at least 98,39725 of 88
Q3 2025at least $102,547,371at least 100,99321 of 83
Q4 2025at least $115,345,961at least 111,92025 of 84

By quarter, 2026 (posted so far)

Q1 2026at least $121,171,872at least 116,36723 of 83

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.